Genomics
The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to.
Research
The verdict
The toll-road of science — a fortress compounder you buy for the next decade, not the next quarter; at ~18x forward EPS it is as cheap as it has been in years precisely because organic growth is stuck at ~2% and the GAAP/adjusted gap is widening, so the bet is that PPI productivity + biopharma normalization + Clario/Olink revenue synergies re-accelerate organic to mid-single-digits before the multiple has to.
Thermo Fisher is the arms dealer of the entire life-sciences economy. It does not discover drugs or run hospitals; it sells the picks, shovels, reagents, instruments, and outsourced manufacturing/clinical services that everyone else in pharma, biotech, academia, and diagnostics depends on. If a molecule moves from a researcher's bench to an approved therapy in a patient's arm, TMO has touched it at four or five points along the way — the pipette and reagent in discovery, the mass spec in analysis, the proteomics panel in biomarker work, the CRO running the trial (PPD), the CDMO making the drug substance, and the fill-finish line putting it in a vial.
Reported through four segments:
Revenue mix: Product $25,965M / Service $18,592M (FY2025) — ~42% of revenue is now services, the structural shift toward recurring, outsourced-pharma economics. Customers: pharma & biotech (the largest and now-recovering bucket), academic & government (~the bucket hit by NIH cuts), industrial & applied, and healthcare/diagnostics. ~125,000 employees. Geography (Q1'26): North America $5,705M (~52%), Europe $2,957M (~27%), Asia-Pacific $1,970M (~18%, China the swing factor), Other $372M.
The business model's genius is diversification of cyclicality: when one end-market is down (academic on NIH cuts), another is recovering (biopharma post-destocking), so the consolidated top line grinds forward even when no single market is booming. The cost is that you can never grow fast — it is a ~$45B super-tanker.
TMO sits in the middle of the life-sciences chain and increasingly owns more of it — vertical integration is the strategy.
Upstream (inputs TMO buys): specialty chemicals & raw reagents, plastics/resins for single-use bioprocessing consumables, precision electronics/optics for instruments (mass spec, electron microscopy), and semiconductor-adjacent components for analytical platforms. The 10-K flags meaningful tariff exposure here — a large share of contract manufacturers, suppliers, and facilities are outside the US, so US-on-import and retaliatory tariffs raise input costs; management offsets via the PPI Business System (global sourcing, price realization).
The company itself: ~125,000 employees; global manufacturing for reagents/consumables/instruments; the Fisher Scientific distribution network (research-&-safety channel) is a moat-grade logistics asset — it is the Amazon of the lab. The 2025 Solventum filtration & separation acquisition pulled upstream purification/filtration membranes in-house (and opened battery/semiconductor/medtech adjacencies). The Sanofi Ridgefield sterile fill-finish site pulled downstream drug-product manufacturing in-house.
Downstream (who buys): the named end customers are the entire biopharma complex — large pharma (Pfizer, Merck, Lilly, Novartis, Roche-as-customer), the biotech long tail, CROs/academia, and diagnostics labs. No disclosed single-customer concentration >10% (the customers.csv is empty; the 10-K does not flag a >10% customer) — revenue is highly fragmented across thousands of accounts, which is itself the anti-concentration moat.
Chokepoints: (1) single-use bioprocessing consumables — a genuine supply chokepoint during COVID, now normalized but a structural growth driver; (2) high-end mass spec / electron microscopy — few credible substitutes (Bruker, Agilent, Waters are the only peers); (3) the CDMO fill-finish capacity — capacity is the constraint, and TMO is buying it. Single-source risk runs the other way here: TMO is the single source for many of its customers, which is the bull case for pricing power.
This is a genuinely wide-moat business — arguably one of the widest in healthcare. Five reinforcing moats:
Bargaining power: strong over suppliers (scale buyer); strong over the fragmented long-tail of customers (validated workflows); weaker over the largest pharma in CDMO/CRO contracts (big pharma negotiates hard, and can in-source) — which is why LPBS margin (14%) is structurally below LSS (36%). Net: the moat is wide and durable; the debate is entirely about growth rate, not moat existence.
All figures, FY2025 vs FY2024, segment income = operating income before certain charges (the company's own basis):
| Segment | FY25 Rev | FY24 Rev | Reported Δ | Organic Δ | Seg income FY25 | Margin FY25 | Margin Δ |
|---|---|---|---|---|---|---|---|
| Life Sciences Solutions | $10,374M | $9,631M | +8% | +3% | $3,768M | 36.3% | −0.1pt |
| Analytical Instruments | $7,554M | $7,463M | +1% | 0% | n/a (table not fully extracted) | ~21.6% YTD '26 | −2.8pt YTD'26 |
| Specialty Diagnostics | $4,676M | $4,512M | +4% | +2% | $1,256M | 26.9% | +1.2pt |
| LPBS | $23,984M | $23,157M | +4% | +1–4% | $3,350M | 14.0% | +0.7pt |
The trend that matters: consolidated organic growth was only ~2% in FY2025 — reported +4% to $44,556M flattered by ~2pt of M&A (Olink, filtration). This is the entire bear/bull crux:
Read: the mix is improving (bioproduction up, COVID rolloff nearly lapped) but the level of organic growth is still sub-trend. The acceleration is sequential and real but slow.
Latest print — Q1 2026 (quarter ended March 28, 2026; reported April 23, 2026):
Guidance — RAISED with the Q1 print:
Balance-sheet flags (FY2025 year-end): cash $9,852M (up from $4,009M — pre-funded for Clario via $3.8B notes), total debt $39,384M, net debt ~$29.5B. Receivables used $0.43B of cash, contract assets/liabilities $0.38B — normal seasonal working-capital, nothing alarming. Tax rate is structurally low — GAAP 7.5% FY25, adjusted 10.4% — a genuine non-GAAP tailwind to watch (any tax-policy normalization is an EPS headwind).
Market reaction (the tell): the stock fell ~7.2% after the strong FY2025 print, and fell again after Q1'26. The market is not paying for adjusted-EPS beats — it is punishing the ~1–2% organic growth and the widening GAAP/adjusted gap. That is the single most important fact in this whole dossier: expectations are set on organic re-acceleration, and the print isn't delivering it yet.
No transcripts on disk; sentiment reconstructed from web call coverage.
Tone arc across the last ~4 calls (Q3'24 → Q4'24 → FY25 → Q1'26):
Recurring phrases (the management vocabulary): "PPI Business System," "productivity improvements," "disciplined capital allocation," "strategic investments," "broad-based." What they stopped saying: "COVID headwind / runoff" is fading from the script as the comparison laps — a structural positive. Net sentiment: improving and credible, but management is deliberately not declaring victory on organic growth — which is the honest read of a ~2% organic year. This is a team that under-promises; the tone is a leading indicator that the 2H'26/2027 organic number should step up.
Peer set = diversified life-sciences tools / CRO-CDMO / diagnostics, NOT the gene-editing biotechs the index tags under genomics. Multiples are **** with source/date or marked not-sourced. Do not treat any unsourced cell as fact.
| Company | Ticker | Mkt cap | Fwd P/E | EV/EBITDA | Notes |
|---|---|---|---|---|---|
| Thermo Fisher | TMO | ~$173–185B | ~18.6x | ~18x | The benchmark; trades below its own 5-yr median P/E ~31x |
| Danaher | DHR | n/a | n/a | n/a | Street "top pick" in tools (Morgan Stanley); Biotech segment +9% |
| Agilent | A | n/a | n/a | n/a | Analytical-instrument pure-play peer |
| Sartorius | SRT.DE | n/a | n/a | n/a | Bioprocessing pure-play; higher-growth, higher-multiple |
| Mettler-Toledo | MTD | n/a | n/a | n/a | FY26 adj EPS guide $46.30–46.95, +8–10% |
| Waters | WAT | n/a | n/a | n/a | LC/MS peer |
| Bruker | BRKR | n/a | n/a | n/a | Mass-spec/EM peer |
| ICON / IQVIA | ICLR / IQV | n/a | n/a | n/a | Pure-play CRO comps for the PPD/LPBS book |
5-yr-avg ROE and dividend yield: n/a (do not fabricate). TMO's dividend is token (<0.5% yield historically) — it is a buyback-and-M&A compounder, not an income name.
The comp read that is sourced and load-bearing: TMO trades at ~18–19x forward EPS and ~18x EV/EBITDA — a multiyear low and a clear discount to its own ~31x 5-yr median, and a discount to the broad "Global Life Sciences industry on ~34.9x and peers on ~40.2x". (Treat the 40.2x "peer" figure cautiously — it likely blends high-multiple biotech; the relevant tools peers like DHR/MTD trade richer than TMO but not at 40x.) Conclusion: TMO is the cheapest it has been in years, on absolute and relative terms, because the market has de-rated growth — which is exactly the setup for a re-rating IF organic growth steps up. That is the trade.
Pattern of >5% moves over the cycle:
What the market actually reacts to for TMO: (1) organic growth rate above all — beats on adjusted EPS via buybacks/M&A get ignored or punished if organic is soft; (2) end-market funding signals (biotech VC funding, NIH appropriations, big-pharma R&D budgets); (3) China/tariff policy; (4) large M&A (positively when accretive/strategic, e.g. Clario; negatively when leverage spikes). The takeaway for sizing a position: the next 1–2 organic-growth prints are the catalyst, not the headline EPS.
Marc Casper (Chairman & CEO). One of the best operator-allocators in healthcare, full stop.
Verdict on management: a clear asset, not a risk. Casper is the reason a low-organic-growth business still compounds adjusted EPS at high-single-digits.
Forensic-analyst lens. Figures unless labeled.
Income statement. Clean by tools-sector standards. The one genuine flag is the GAAP→adjusted bridge: GAAP diluted EPS $17.74 vs adjusted $22.87 (FY25) — a ~$5.13/share (~29%) gap, driven mostly by acquisition-related intangible amortization ($430M in Q1'26 alone) and restructuring. This is real GAAP expense the adjusted number excludes; it is industry-standard for serial acquirers but means GAAP earnings quality lags the adjusted narrative — a perennial bear talking point. Restructuring/"other" costs are recurring ($362M FY25, $49M Q1'26) — i.e. "one-time" restructuring is effectively a standing line item.
Balance sheet. Goodwill + intangibles dominate assets (~$49B goodwill on $110.3B total assets) — impairment risk if a major acquired business underperforms, though no impairment was taken. Leverage: total debt $39,384M YE2025, rising toward ~$43B post-Clario; net debt/EBITDA ~3.5x per Street — elevated for TMO's historical ~2–3x but manageable at investment grade given $6B+ FCF; it does constrain the next mega-deal. Pension and contingencies are immaterial.
Cash flow vs earnings. No red flag — the opposite. FY2025 operating cash flow $7,818M vs net income $6,721M (>1.0x conversion); FCF $6,337M. Q1'26 FCF more than doubled YoY. Cash generation validates earnings — there is no accrual/receivables divergence story here. (Receivables +$0.43B and contract assets +$0.38B in FY25 are ordinary working-capital, well within revenue growth.) SBC is modest for the sector and does not flatter the adjusted number the way it does at high-growth tech.
Segment reporting. Transparent — four clean segments with organic/M&A/FX bridges and segment-income margins disclosed. No opaque "corporate/other" dumping ground beyond standard unallocated amortization/interest.
Regulatory findings (required sub-section):
Forensic verdict: clean books, strong cash conversion, investment-grade leverage. The only legitimate forensic critiques are (a) the structural GAAP-vs-adjusted gap from serial-M&A amortization and (b) goodwill-heavy balance sheet — both inherent to the roll-up model, neither a fraud/quality red flag. This is a high-trust set of financials.
Built bottom-up from FY2025 actuals + management's own raised FY2026 guide. Output ****; inputs labeled.
Anchor: FY2025 adjusted EPS $22.87. FY2026 company guide $24.64–25.12, consensus ~$24.81.
| FY2026E | FY2027E | FY2028E | |
|---|---|---|---|
| Revenue | ~$47.7B (guide midpoint, +7%) | ~$50.5B | ~$53.5B |
| Adj operating margin | ~22.5% | ~23% | ~23.5% |
| Adj EPS | ~$24.88 | ~$27.6 | ~$30.5 |
The EPS algorithm: mid-single-digit revenue + modest margin expansion (PPI) + ~2–3%/yr share-count reduction (the $5B+ buyback cadence) ≈ low-double-digit adjusted-EPS growth, even with only ~mid-single-digit organic revenue. That is the compounding engine, and it works as long as (a) organic recovers to mid-SD and (b) the balance sheet supports continued buybacks/M&A. Base case: adjusted EPS roughly $25 → $27.5 → $30.5 over FY26–28E. GAAP EPS runs ~$5–6/share below adjusted on amortization.
(Per --watchlist rules, no forecast.ts create logged in this unattended sweep. Forecast-worthy base call for a future log: "TMO FY2026 adjusted EPS ≥ $24.64," p≈0.80, resolves 2026-12-31 — management-guided, high confidence.)
Bull case. TMO is a fortress compounder bought at a multiyear-low multiple. (1) Moat is uncontested — the only end-to-end discovery-to-fill-finish platform; switching costs + Fisher distribution + PPI are durable. (2) The cycle is turning — COVID rolloff is nearly lapped, biotech funding is recovering, bioproduction is reaccelerating; Q1'26 management tone is the most confident in two years. (3) Capital allocation compounds — ~$6–8B FCF/yr funds accretive M&A (Clario/Olink/filtration) + a falling share count, delivering ~10% adjusted-EPS growth on ~mid-SD revenue. (4) Valuation — ~18x forward EPS / ~18x EV/EBITDA vs a ~31x own-history median; a re-rate toward even 22–24x on proof of organic re-acceleration is ~20–30% upside before earnings growth. (5) Earnings-surprise potential — operating leverage on any organic upside is high; A&G is so de-rated that mere stabilization (not recovery) of NIH funding is a positive surprise. 27 sell-side buys / 0 sells; targets to ~$659.
Bear case (permanent-impairment lens). (1) Structural growth has slowed to ~2% organic — if life-sciences-tools is now a 3–5% market (not the 6–8% of the 2010s) and TMO grows in line, the stock deserves a lower multiple than its history, and there is no re-rate — you've bought a 5% revenue grower at a fair price, full stop. (2) The adjusted-EPS engine is increasingly financial, not operational — ~3pt of Q1'26 growth was M&A, organic 1%; if the market keeps refusing to pay for buyback-/M&A-driven EPS, multiple stays capped regardless of EPS. (3) Policy regime change is structural, not cyclical — a durably smaller NIH ($500M A&G hit already) + persistent tariffs + a structurally weaker China could keep organic muted for years. Pre-mortem (18 months out, thesis broke): NIH appropriations were cut again, China stayed negative, biotech funding stalled, organic never broke above ~3%, the GAAP/adjusted gap widened with each new deal, and TMO de-rated to ~16x as the market concluded it is a low-growth industrial — the stock went sideways-to-down while the S&P compounded. Is the multiple too high? No — at ~18x it is not demanding; the risk is a value trap (cheap and stays cheap), not an expensive-stock blow-up.
Contrarian view (what the market refuses to see): the market is treating TMO as a broken growth story and pricing it like a slow industrial, but it is mis-weighting the mix shift — bioproduction + pharma-services (the high-quality, recurring, secular-growth books) are quietly becoming a larger share of revenue while the cyclical/policy-exposed buckets (academic instruments, COVID, China) shrink as a share. The organic number that looks stuck at ~2% is a blended average masking a high-quality core compounding at high-single-digits underneath a melting-ice-cube of COVID/A&G drag. As the drag fully laps in 2026–27, blended organic should step toward the quality core's rate — and that is the re-rate catalyst the market is currently refusing to underwrite.
Skeptical short dismantling the bull.
Not a stock anymore — a closed M&A. Lilly bought the whole company for $10.50/share cash (closed Jul 2025); the only live "position" is the $3.00 CVR, which pays only if VERVE-102 reaches a US Phase 3 dosing — market priced ~21% odds, a coin-flip dressed as a lottery ticket.
A one-asset, binary bet on a genuinely best-in-class disease-modifying Dravet drug whose pivotal read-out (mid-2027) lands inside a fully-funded runway — own it for the read-out, but size it like the 50/50 single-trial event it is.
A David Liu-pedigreed prime-editing pioneer cornered into a defensive crouch — 25% RIF, founder-CEO out, lead CGD asset demoted to a partnering candidate, going-concern doubt at ~14 months of cash, and an existential Beam IP arbitration over one of its two surviving lead programs. At a ~$537M cap it is a deeply discounted binary call option on 2027 first-in-human liver data; bullish only for risk-seeking capital that can survive a dilution-or-bust 2026.